New combo attack on kidney cancer: radiation plus two drugs
NCT ID NCT07470840
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will test a combination of precise radiation (SBRT) and two drugs—anlotinib (which cuts off tumor blood supply) and bemarituzumab (which boosts the immune system)—in 27 people with advanced kidney cancer that cannot be surgically removed. The main goal is to see how many patients' tumors shrink significantly. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anlotinib (oral anti-angiogenic drug) and bemarituzumab (intravenous immunotherapy), plus stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this combination could offer a new treatment option that shrinks tumors and delays progression in advanced kidney cancer.
What could go wrong
This is a small, early-phase trial (27 people) with no results yet. The combination may cause significant side effects, and the benefit may not be confirmed in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••